Patrick Arbuthnot
Overview
Explore the profile of Patrick Arbuthnot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mnyandu N, Limani S, Ely A, Wadee R, Arbuthnot P, Maepa M
Virol J
. 2025 Feb;
22(1):41.
PMID: 39962472
Current treatments for chronic infection with the hepatitis B virus (HBV) rarely cure carriers from the disease. Previously reported use of serotype 8 adeno-associated viral (AAV8) vectors to deliver expression...
2.
Mnyandu N, Jacobs R, Arbuthnot P, Maepa M
Pharmaceutics
. 2024 Nov;
16(11).
PMID: 39598484
Over 80% of the world's deadliest pandemics are caused by viral infections, and vaccination remains the most effective way to prevent these infections from spreading. Since the discovery of the...
3.
Bloom K, Ely A, Maepa M, Arbuthnot P
Gene Ther
. 2024 Nov;
32(1):4-7.
PMID: 39558149
No abstract available.
4.
M Abkallo H, Arbuthnot P, Auer T, Berger D, Burger J, Chakauya E, et al.
Nat Biotechnol
. 2024 Mar;
42(4):551-554.
PMID: 38504013
No abstract available.
5.
Jacobs R, Dogbey M, Mnyandu N, Neves K, Barth S, Arbuthnot P, et al.
Microorganisms
. 2023 Dec;
11(12).
PMID: 38138129
Hepatitis B virus (HBV) has afflicted humankind for decades and there is still no treatment that can clear the infection. The development of recombinant adeno-associated virus (rAAV)-based gene therapy for...
6.
Kana B, Arbuthnot P, Botwe B, Choonara Y, Hassan F, Louzir H, et al.
Lancet Infect Dis
. 2023 Jun;
23(8):e288-e300.
PMID: 37290473
The COVID-19 pandemic heralded unprecedented resource mobilisation and global scientific collaboration to rapidly develop effective vaccines. Regrettably, vaccine distribution has been inequitable, particularly in Africa where manufacturing capacity remains nominal....
7.
Kairuz D, Samudh N, Ely A, Arbuthnot P, Bloom K
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111658
Africa bears the highest burden of infectious diseases, yet the continent is heavily reliant on First World countries for the development and supply of life-saving vaccines. The COVID-19 pandemic was...
8.
Farhad T, Neves K, Arbuthnot P, Maepa M
Genes (Basel)
. 2022 Nov;
13(11).
PMID: 36360178
Adenoviral vaccines have been at the front line in the fight against pandemics caused by viral infections such as Ebola and the coronavirus disease 2019. This has revived an interest...
9.
Kairuz D, Samudh N, Ely A, Arbuthnot P, Bloom K
Front Immunol
. 2022 Nov;
13:1018961.
PMID: 36353641
Synthetic mRNA technologies represent a versatile platform that can be used to develop advanced drug products. The remarkable speed with which vaccine development programs designed and manufactured safe and effective...
10.
Maepa M, Ely A, Kramvis A, Bloom K, Naidoo K, Simani O, et al.
Viruses
. 2022 Sep;
14(9).
PMID: 36146747
Despite being vaccine-preventable, hepatitis B virus (HBV) infection remains the seventh leading cause of mortality in the world. In South Africa (SA), over 1.9 million people are chronically infected with...